Page 3 - Nasdaq Cbay News Today

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective hoisted by Raymond James from $33.00 to $34.00 in a report issued on Wednesday morning, Benzinga reports. Raymond James currently has a strong-buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently commented on the stock. B. Riley lifted their […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its target price hoisted by Piper Sandler from $19.00 to $33.00 in a research note released on Monday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on CBAY. Cantor Fitzgerald reiterated an overweight rating and […]

Arizona State Retirement System reduced its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 16.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,496 shares of the biopharmaceutical company’s stock after selling 4,040 shares during the […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect CymaBay Therapeutics to post earnings of ($0.30) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. CymaBay Therapeutics (NASDAQ:CBAY – […]

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have earned a consensus rating of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target […]

Moody Aldrich Partners LLC bought a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 115,340 shares of the biopharmaceutical company’s stock, valued at approximately $1,263,000. A number of other hedge […]

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target lifted by UBS Group from $18.00 to $25.00 in a research report sent to investors on Tuesday, Marketbeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock. CBAY has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 21,746 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $16.22, for a total value of $352,720.12. Following the sale, the insider now directly owns 15,000 shares of the company’s stock, […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 53,000 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $16.87, for a total transaction of $894,110.00. The transaction was disclosed in a document filed with the Securities & […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 8,960,000 shares, a decrease of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily volume of 2,410,000 shares, […]